Tempus AI, Inc. (NASDAQ:TEM) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Tempus AI, Inc. (NASDAQ:TEM) have earned an average rating of “Moderate Buy” from the fourteen analysts that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $68.6429.

A number of research analysts have recently issued reports on TEM shares. Guggenheim cut their target price on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, March 30th. TD Cowen raised their price target on Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research report on Wednesday, March 11th. BTIG Research reduced their price objective on Tempus AI from $90.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Finally, Stifel Nicolaus set a $60.00 target price on Tempus AI in a report on Wednesday, February 25th.

Tempus AI Trading Up 1.3%

Shares of Tempus AI stock opened at $46.49 on Friday. The stock has a market capitalization of $8.35 billion, a P/E ratio of -27.03 and a beta of 3.99. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The company has a 50-day simple moving average of $49.02 and a 200 day simple moving average of $59.39. Tempus AI has a 12-month low of $41.73 and a 12-month high of $104.32.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.24) earnings per share. Research analysts expect that Tempus AI will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, CFO James William Rogers sold 10,853 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $478,291.71. Following the sale, the chief financial officer owned 126,395 shares of the company’s stock, valued at $5,570,227.65. This represents a 7.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 8,703 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $383,541.21. Following the completion of the transaction, the executive vice president directly owned 128,215 shares of the company’s stock, valued at approximately $5,650,435.05. This represents a 6.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 392,057 shares of company stock worth $18,835,714 over the last quarter. Corporate insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

Hedge funds have recently added to or reduced their stakes in the company. JPL Wealth Management LLC acquired a new stake in Tempus AI during the 3rd quarter worth $26,000. Los Angeles Capital Management LLC bought a new stake in shares of Tempus AI in the 4th quarter valued at about $27,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Tempus AI in the 3rd quarter valued at about $38,000. Tsfg LLC raised its position in shares of Tempus AI by 1,515.2% in the 3rd quarter. Tsfg LLC now owns 533 shares of the company’s stock valued at $43,000 after acquiring an additional 500 shares during the period. Finally, Cloud Capital Management LLC bought a new position in Tempus AI during the 3rd quarter worth approximately $44,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.